These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 15827203)

  • 1. Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes.
    Khan MA; Kao S; Miyagi E; Takeuchi H; Goila-Gaur R; Opi S; Gipson CL; Parslow TG; Ly H; Strebel K
    J Virol; 2005 May; 79(9):5870-4. PubMed ID: 15827203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the contribution of cellular and viral RNA to the packaging of APOBEC3G into HIV-1 virions.
    Khan MA; Goila-Gaur R; Opi S; Miyagi E; Takeuchi H; Kao S; Strebel K
    Retrovirology; 2007 Jul; 4():48. PubMed ID: 17631688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging.
    Luo K; Liu B; Xiao Z; Yu Y; Yu X; Gorelick R; Yu XF
    J Virol; 2004 Nov; 78(21):11841-52. PubMed ID: 15479826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant.
    Opi S; Kao S; Goila-Gaur R; Khan MA; Miyagi E; Takeuchi H; Strebel K
    J Virol; 2007 Aug; 81(15):8236-46. PubMed ID: 17522211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. APOBEC3G multimers are recruited to the plasma membrane for packaging into human immunodeficiency virus type 1 virus-like particles in an RNA-dependent process requiring the NC basic linker.
    Burnett A; Spearman P
    J Virol; 2007 May; 81(10):5000-13. PubMed ID: 17344295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs.
    Svarovskaia ES; Xu H; Mbisa JL; Barr R; Gorelick RJ; Ono A; Freed EO; Hu WS; Pathak VK
    J Biol Chem; 2004 Aug; 279(34):35822-8. PubMed ID: 15210704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNA and DNA binding properties of HIV-1 Vif protein: a fluorescence study.
    Bernacchi S; Henriet S; Dumas P; Paillart JC; Marquet R
    J Biol Chem; 2007 Sep; 282(36):26361-8. PubMed ID: 17609216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. APOBEC3G incorporation into human immunodeficiency virus type 1 particles.
    Zennou V; Perez-Caballero D; Göttlinger H; Bieniasz PD
    J Virol; 2004 Nov; 78(21):12058-61. PubMed ID: 15479846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monomeric APOBEC3G is catalytically active and has antiviral activity.
    Opi S; Takeuchi H; Kao S; Khan MA; Miyagi E; Goila-Gaur R; Iwatani Y; Levin JG; Strebel K
    J Virol; 2006 May; 80(10):4673-82. PubMed ID: 16641260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 and MLV Gag proteins are sufficient to recruit APOBEC3G into virus-like particles.
    Douaisi M; Dussart S; Courcoul M; Bessou G; Vigne R; Decroly E
    Biochem Biophys Res Commun; 2004 Aug; 321(3):566-73. PubMed ID: 15358144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. APOBEC3G ubiquitination by Nedd4-1 favors its packaging into HIV-1 particles.
    Dussart S; Douaisi M; Courcoul M; Bessou G; Vigne R; Decroly E
    J Mol Biol; 2005 Jan; 345(3):547-58. PubMed ID: 15581898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The interaction between HIV-1 Gag and APOBEC3G.
    Cen S; Guo F; Niu M; Saadatmand J; Deflassieux J; Kleiman L
    J Biol Chem; 2004 Aug; 279(32):33177-84. PubMed ID: 15159405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor.
    Schäfer A; Bogerd HP; Cullen BR
    Virology; 2004 Oct; 328(2):163-8. PubMed ID: 15464836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cooperative and specific binding of Vif to the 5' region of HIV-1 genomic RNA.
    Henriet S; Richer D; Bernacchi S; Decroly E; Vigne R; Ehresmann B; Ehresmann C; Paillart JC; Marquet R
    J Mol Biol; 2005 Nov; 354(1):55-72. PubMed ID: 16236319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [HIV-1, a very Vif virus].
    Schwartz O
    Med Sci (Paris); 2004 Feb; 20(2):139-41. PubMed ID: 14997428
    [No Abstract]   [Full Text] [Related]  

  • 16. Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G.
    Kaiser SM; Emerman M
    J Virol; 2006 Jan; 80(2):875-82. PubMed ID: 16378989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human APOBEC3G incorporation into murine leukemia virus particles.
    Kremer M; Bittner A; Schnierle BS
    Virology; 2005 Jun; 337(1):175-82. PubMed ID: 15914230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. APOBEC3G & HTLV-1: inhibition without deamination.
    Strebel K
    Retrovirology; 2005 May; 2():37. PubMed ID: 15921532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation.
    Luo K; Wang T; Liu B; Tian C; Xiao Z; Kappes J; Yu XF
    J Virol; 2007 Jul; 81(13):7238-48. PubMed ID: 17428847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. APOBEC3G-independent reduction in virion infectivity during long-term HIV-1 replication in terminally differentiated macrophages.
    Miyagi E; Schwartzkopff F; Plishka R; Buckler-White A; Clouse KA; Strebel K
    Virology; 2008 Sep; 379(2):266-74. PubMed ID: 18675436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.